← Eichor
Study identifier: NCT07549516 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

Condition: Leukemia, Chronic Myeloid  ·  Sponsor: Novartis Pharmaceuticals

PhaseN/A
Planned participants380
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals  ·  +41613241111  ·  novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (54)

Novartis Investigative SiteBaden-Baden, Baden-Wurttemberg, GermanyRecruiting
Novartis Investigative SiteHeidenheim, Baden-Wurttemberg, GermanyRecruiting
Novartis Investigative SiteSchwäbisch Hall, Baden-Wurttemberg, GermanyRecruiting
Novartis Investigative SiteAschaffenburg, Bavaria, GermanyRecruiting
Novartis Investigative SiteAugsburg, Bavaria, GermanyRecruiting
Novartis Investigative SiteDonauwörth, Bavaria, GermanyRecruiting
Novartis Investigative SiteHerrsching am Ammersee, Bavaria, GermanyRecruiting
Novartis Investigative SiteKempten (Allgäu), Bavaria, GermanyRecruiting
Novartis Investigative SiteLandsberg am Lech, Bavaria, GermanyRecruiting
Novartis Investigative SiteMunich, Bavaria, GermanyRecruiting
Novartis Investigative SiteRegensburg, Bavaria, GermanyRecruiting
Novartis Investigative SiteBremerhaven, Free Hanseatic City of Bremen, GermanyRecruiting

+ 42 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07549516